Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Sep;200(9):805-814.
doi: 10.1007/s00066-024-02242-6. Epub 2024 Jun 3.

Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China

Shaohong Luo  1   2 , Shufei Lai  1   2   3 , Yajing Wu  1   2   3 , Jinsheng Hong  4   5   6 , Dong Lin  1   2 , Shen Lin  1   2 , Xiaoting Huang  1   2 , Xiongwei Xu  1   2 , Xiuhua Weng  7   8
Affiliations
Comparative Study

Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China

Shaohong Luo et al. Strahlenther Onkol. 2024 Sep.

Abstract

Background: Bevacizumab shows superior efficacy in cerebral radiation necrosis (CRN) therapy, but its economic burden remains heavy due to the high drug price. This study aims to evaluate the cost-effectiveness of bevacizumab for CRN treatment from the Chinese payers' perspective.

Methods: A decision tree model was developed to compare the costs and health outcomes of bevacizumab and corticosteroids for CRN therapy. Efficacy and safety data were derived from the NCT01621880 trial, which compared the effectiveness and safety of bevacizumab monotherapy with corticosteroids for CRN in nasopharyngeal cancer patients, and demonstrated that bevacizumab invoked a significantly higher response than corticosteroids (65.5% vs. 31.5%, P < 0.001) with no significant differences in adverse events between two groups. The utility value of the "non-recurrence" status was derived from real-world data. Costs and other utility values were collected from an authoritative Chinese network database and published literature. The primary outcomes were total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). The uncertainty of the model was evaluated via one-way and probabilistic sensitivity analyses.

Results: Bevacizumab treatment added 0.12 (0.48 vs. 0.36) QALYs compared to corticosteroid therapy, along with incremental costs of $ 2010 ($ 4260 vs. $ 2160). The resultant ICER was $ 16,866/QALY, which was lower than the willingness-to-pay threshold of $ 38,223/QALY in China. The price of bevacizumab, body weight, and the utility value of recurrence status were the key influential parameters for ICER. Probabilistic sensitivity analysis revealed that the probability of bevacizumab being cost-effectiveness was 84.9%.

Conclusion: Compared with corticosteroids, bevacizumab is an economical option for CRN treatment in China.

Keywords: Bevacizumab monotherapy; Corticosteroids; Pharmacoeconomics; Tumor complications; Value-based pricing.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Reirradiation for recurrent glioblastoma: the significance of the residual tumor volume.
    Mansoorian S, Schmidt M, Weissmann T, Delev D, Heiland DH, Coras R, Stritzelberger J, Saake M, Höfler D, Schubert P, Schmitter C, Lettmaier S, Filimonova I, Frey B, Gaipl US, Distel LV, Semrau S, Bert C, Eze C, Schönecker S, Belka C, Blümcke I, Uder M, Schnell O, Dörfler A, Fietkau R, Putz F. Mansoorian S, et al. J Neurooncol. 2025 Aug;174(1):243-252. doi: 10.1007/s11060-025-05042-9. Epub 2025 May 1. J Neurooncol. 2025. PMID: 40310485 Free PMC article.

References

    1. Zhuang H, Shi S, Yuan Z et al (2019) Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Mol Cancer 18(1):21. https://doi.org/10.1186/s12943-019-0950-1 - DOI - PubMed - PMC
    1. Munier S, Ginalis EE, Patel NV et al (2020) Radiation necrosis in intracranial lesions. Cureus 12(4):e7603. https://doi.org/10.7759/cureus.7603 - DOI - PubMed - PMC
    1. Ali FS, Arevalo O, Zorofchian S et al (2019) Cerebral radiation necrosis: incidence, pathogenesis, diagnostic challenges, and future opportunities. Curr Oncol Rep 21(8):66. https://doi.org/10.1007/s11912-019-0818-y - DOI - PubMed
    1. Rahmathulla G, Marko NF, Weil RJ (2013) Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. J Clin Neurosci 20(4):485–502. https://doi.org/10.1016/j.jocn.2012.09.011 - DOI - PubMed
    1. Lawrence YR, Li XA, el Naqa I et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76(3 Suppl):S20–S27. https://doi.org/10.1016/j.ijrobp.2009.02.091 - DOI - PubMed - PMC

Publication types

MeSH terms

Associated data

LinkOut - more resources